Incidence rate*ratios for lymphoid neoplasms by subtype, race, and sex, 12 SEER registries, 1992-2001
. | Male-female IRR . | . | . | White-black IRR . | . | White-Asian IRR . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphoid neoplasm subtype . | White . | Black . | Asian . | Males . | Females . | Males . | Females . | ||||
| Lymphoid neoplasms, total | 1.6 | 1.5 | 1.5 | 1.1 | 1.1 | 1.7 | 1.7 | ||||
| B-cell lymphoid neoplasms, total | 1.6 | 1.5 | 1.5 | 1.1 | 1.0 | 1.7 | 1.6 | ||||
| DLBCL | 1.6 | 1.8 | 1.4 | 1.5 | 1.6 | 1.3 | 1.2 | ||||
| Marginal zone lymphoma | 1.0 | 1.1 | 1.2 | 1.2 | 1.4 | 0.8 | 1.0 | ||||
| Follicular lymphoma | 1.2 | 1.6 | 1.2 | 2.1 | 2.8 | 2.4 | 2.4 | ||||
| CLL/SLL | 1.9 | 2.0 | 1.9 | 1.3 | 1.4 | 4.4 | 4.3 | ||||
| Mantle cell lymphoma | 2.5 | 1.9 | 1.8 | 1.9 | 1.5 | 2.6 | 1.9 | ||||
| Burkitt lymphoma/leukemia | 3.3 | 3.8 | 2.2 | 1.2 | 1.4 | 1.3 | 0.9 | ||||
| Plasma cell neoplasms | 1.6 | 1.3 | 1.5 | 0.5 | 0.4 | 1.6 | 1.5 | ||||
| Multiple myeloma | 1.5 | 1.3 | 1.4 | 0.5 | 0.4 | 1.6 | 1.5 | ||||
| Plasma cell leukemia | 1.6 | 1.0 | –† | 0.5 | 0.3 | –† | 1.2 | ||||
| Plasmacytoma | 2.2 | 1.5 | 3.0 | 0.8 | 0.6 | 1.7 | 2.3 | ||||
| Hairy cell leukemia | 3.8 | 3.7 | 5.5 | 3.0 | 2.9 | 3.1 | 4.5 | ||||
| Lymphoplasmacytic lymphoma | 1.5 | 1.1 | 3.1 | 1.2 | 0.8 | 1.2 | 2.3 | ||||
| Waldenström macroglobulinemia | 2.2 | 2.6 | 2.3 | 2.2 | 2.6 | 1.8 | 1.8 | ||||
| B-cell lymphoid neoplasms, NOS | 1.5 | 1.9 | 1.5 | 1.2 | 1.5 | 1.1 | 1.1 | ||||
| T/NK-cell lymphoid neoplasms, total | 1.9 | 1.5 | 1.9 | 0.9 | 0.7 | 1.1 | 1.1 | ||||
| Mycosis fungoides/Sézary syndrome | 1.8 | 1.2 | 1.8 | 0.7 | 0.5 | 1.4 | 1.4 | ||||
| Peripheral T-cell lymphoma | 1.8 | 1.7 | 1.6 | 0.8 | 0.7 | 0.9 | 0.8 | ||||
| Angioimmunoblastic lymphoma | 1.3 | 2.0 | 1.7 | 0.8 | 1.2 | 0.5 | 0.7 | ||||
| Anaplastic large-cell lymphoma | 1.9 | 2.0 | 1.3 | 0.9 | 0.9 | 1.9 | 1.3 | ||||
| Peripheral T-cell lymphoma, NOS | 1.8 | 1.5 | 1.7 | 0.7 | 0.6 | 0.7 | 0.6 | ||||
| T/NK-cell lymphoid neoplasms, NOS | 2.0 | 1.7 | 2.4 | 1.1 | 0.9 | 1.1 | 1.3 | ||||
| Lymphoblastic leukemia/lymphoma | 1.4 | 1.3 | 1.4 | 1.9 | 1.8 | 1.3 | 1.3 | ||||
| B-cell lymphoblastic leukemia/lymphoma | 1.3 | 1.3 | 1.1 | 2.3 | 2.3 | 1.3 | 1.1 | ||||
| T-cell lymphoblastic leukemia/lymphoma | 2.4 | 1.8 | 2.0 | 1.1 | 0.8 | 1.1 | 1.0 | ||||
| Unknown type lymphoblastic leukemia/lymphoma | 1.2 | 1.2 | 1.6 | 2.0 | 1.8 | 1.3 | 1.7 | ||||
| Prolymphocytic leukemia | 2.6 | 1.4 | 3.2 | 1.7 | 0.9 | 3.3 | 4.1 | ||||
| Hodgkin lymphoma | 1.2 | 1.4 | 1.3 | 1.2 | 1.3 | 2.8 | 2.9 | ||||
| Classical Hodgkin lymphoma | 1.2 | 1.4 | 1.3 | 1.2 | 1.4 | 2.8 | 3.0 | ||||
| Nodular sclerosis | 1.0 | 1.0 | 1.1 | 1.4 | 1.4 | 3.0 | 3.4 | ||||
| Mixed cellularity/lymphocyte depleted | 2.0 | 2.9 | 1.8 | 1.0 | 1.4 | 2.4 | 2.1 | ||||
| Classical Hodgkin lymphoma, NOS | 1.8 | 1.9 | 1.6 | 1.0 | 1.0 | 2.9 | 2.5 | ||||
| Nodular lymphocyte predominant Hodgkin lymphoma | 3.0 | 1.2 | 0.9 | 0.6 | 0.2 | 5.0 | 1.5 | ||||
| Unknown type lymphoid neoplasms | 1.8 | 2.1 | 1.9 | 1.0 | 1.2 | 1.9 | 2.0 | ||||
. | Male-female IRR . | . | . | White-black IRR . | . | White-Asian IRR . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphoid neoplasm subtype . | White . | Black . | Asian . | Males . | Females . | Males . | Females . | ||||
| Lymphoid neoplasms, total | 1.6 | 1.5 | 1.5 | 1.1 | 1.1 | 1.7 | 1.7 | ||||
| B-cell lymphoid neoplasms, total | 1.6 | 1.5 | 1.5 | 1.1 | 1.0 | 1.7 | 1.6 | ||||
| DLBCL | 1.6 | 1.8 | 1.4 | 1.5 | 1.6 | 1.3 | 1.2 | ||||
| Marginal zone lymphoma | 1.0 | 1.1 | 1.2 | 1.2 | 1.4 | 0.8 | 1.0 | ||||
| Follicular lymphoma | 1.2 | 1.6 | 1.2 | 2.1 | 2.8 | 2.4 | 2.4 | ||||
| CLL/SLL | 1.9 | 2.0 | 1.9 | 1.3 | 1.4 | 4.4 | 4.3 | ||||
| Mantle cell lymphoma | 2.5 | 1.9 | 1.8 | 1.9 | 1.5 | 2.6 | 1.9 | ||||
| Burkitt lymphoma/leukemia | 3.3 | 3.8 | 2.2 | 1.2 | 1.4 | 1.3 | 0.9 | ||||
| Plasma cell neoplasms | 1.6 | 1.3 | 1.5 | 0.5 | 0.4 | 1.6 | 1.5 | ||||
| Multiple myeloma | 1.5 | 1.3 | 1.4 | 0.5 | 0.4 | 1.6 | 1.5 | ||||
| Plasma cell leukemia | 1.6 | 1.0 | –† | 0.5 | 0.3 | –† | 1.2 | ||||
| Plasmacytoma | 2.2 | 1.5 | 3.0 | 0.8 | 0.6 | 1.7 | 2.3 | ||||
| Hairy cell leukemia | 3.8 | 3.7 | 5.5 | 3.0 | 2.9 | 3.1 | 4.5 | ||||
| Lymphoplasmacytic lymphoma | 1.5 | 1.1 | 3.1 | 1.2 | 0.8 | 1.2 | 2.3 | ||||
| Waldenström macroglobulinemia | 2.2 | 2.6 | 2.3 | 2.2 | 2.6 | 1.8 | 1.8 | ||||
| B-cell lymphoid neoplasms, NOS | 1.5 | 1.9 | 1.5 | 1.2 | 1.5 | 1.1 | 1.1 | ||||
| T/NK-cell lymphoid neoplasms, total | 1.9 | 1.5 | 1.9 | 0.9 | 0.7 | 1.1 | 1.1 | ||||
| Mycosis fungoides/Sézary syndrome | 1.8 | 1.2 | 1.8 | 0.7 | 0.5 | 1.4 | 1.4 | ||||
| Peripheral T-cell lymphoma | 1.8 | 1.7 | 1.6 | 0.8 | 0.7 | 0.9 | 0.8 | ||||
| Angioimmunoblastic lymphoma | 1.3 | 2.0 | 1.7 | 0.8 | 1.2 | 0.5 | 0.7 | ||||
| Anaplastic large-cell lymphoma | 1.9 | 2.0 | 1.3 | 0.9 | 0.9 | 1.9 | 1.3 | ||||
| Peripheral T-cell lymphoma, NOS | 1.8 | 1.5 | 1.7 | 0.7 | 0.6 | 0.7 | 0.6 | ||||
| T/NK-cell lymphoid neoplasms, NOS | 2.0 | 1.7 | 2.4 | 1.1 | 0.9 | 1.1 | 1.3 | ||||
| Lymphoblastic leukemia/lymphoma | 1.4 | 1.3 | 1.4 | 1.9 | 1.8 | 1.3 | 1.3 | ||||
| B-cell lymphoblastic leukemia/lymphoma | 1.3 | 1.3 | 1.1 | 2.3 | 2.3 | 1.3 | 1.1 | ||||
| T-cell lymphoblastic leukemia/lymphoma | 2.4 | 1.8 | 2.0 | 1.1 | 0.8 | 1.1 | 1.0 | ||||
| Unknown type lymphoblastic leukemia/lymphoma | 1.2 | 1.2 | 1.6 | 2.0 | 1.8 | 1.3 | 1.7 | ||||
| Prolymphocytic leukemia | 2.6 | 1.4 | 3.2 | 1.7 | 0.9 | 3.3 | 4.1 | ||||
| Hodgkin lymphoma | 1.2 | 1.4 | 1.3 | 1.2 | 1.3 | 2.8 | 2.9 | ||||
| Classical Hodgkin lymphoma | 1.2 | 1.4 | 1.3 | 1.2 | 1.4 | 2.8 | 3.0 | ||||
| Nodular sclerosis | 1.0 | 1.0 | 1.1 | 1.4 | 1.4 | 3.0 | 3.4 | ||||
| Mixed cellularity/lymphocyte depleted | 2.0 | 2.9 | 1.8 | 1.0 | 1.4 | 2.4 | 2.1 | ||||
| Classical Hodgkin lymphoma, NOS | 1.8 | 1.9 | 1.6 | 1.0 | 1.0 | 2.9 | 2.5 | ||||
| Nodular lymphocyte predominant Hodgkin lymphoma | 3.0 | 1.2 | 0.9 | 0.6 | 0.2 | 5.0 | 1.5 | ||||
| Unknown type lymphoid neoplasms | 1.8 | 2.1 | 1.9 | 1.0 | 1.2 | 1.9 | 2.0 | ||||
Italicized IRRs were not statistically significant at P < .05 (95% CI included 1.0); 95% CIs available from the author.
IRR indicates incidence rate ratio; other abbreviations are explained in Table 1.
All incidence rates are age adjusted to the 2000 United States population
Calculation of the IRR was precluded by zero cases diagnosed among Asian males